Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the clinical management of multiple cancer types, however, many tumors still fail to respond. CCL2 is highly expressed in various cancer types and has been shown to be associated with poor prognosis. Inhibition or blockade of the CC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Commun Biol
Main Authors: Tu, Megan M., Abdel-Hafiz, Hany A., Jones, Robert T., Jean, Annie, Hoff, Katelyn J., Duex, Jason E., Chauca-Diaz, Ana, Costello, James C., Dancik, Garrett M., Tamburini, Beth A. Jirón, Czerniak, Bogdan, Kaye, Jonathan, Theodorescu, Dan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699641/
https://ncbi.nlm.nih.gov/pubmed/33247183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-020-01441-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados